Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CHUCNASDAQ:CLNNNASDAQ:GRCEOTCMKTS:INTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHUCCharlie's$0.11-1.4%$0.09$0.03▼$0.20$27.12M0.9871,875 shs36,109 shsCLNNClene$4.33+7.7%$2.94$2.28▼$9.20$38.90M0.4988,010 shs127,368 shsGRCEGrace Therapeutics$2.96+2.8%$2.53$1.75▼$4.97$30.01M0.8955,224 shs13,497 shsINTIInhibitor Therapeutics$0.05+8.0%$0.05$0.03▼$0.10$9.32M-0.4336,322 shs6,350 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHUCCharlie's-1.40%+21.29%-2.04%+191.97%+9.11%CLNNClene+7.71%+58.03%+52.46%-5.46%-34.59%GRCEGrace Therapeutics+2.78%+2.07%+0.34%+16.54%+295,999,900.00%INTIInhibitor Therapeutics+8.00%+10.43%+8.00%-16.92%-22.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHUCCharlie's0.9965 of 5 stars0.05.00.00.02.01.70.0CLNNClene2.3305 of 5 stars3.63.00.00.00.62.50.6GRCEGrace Therapeutics2.7889 of 5 stars3.50.00.00.03.80.81.3INTIInhibitor TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHUCCharlie's 0.00N/AN/AN/ACLNNClene 3.17Buy$40.00823.79% UpsideGRCEGrace Therapeutics 3.00Buy$12.00305.41% UpsideINTIInhibitor Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INTI, GRCE, CLNN, and CHUC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/12/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/12/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHUCCharlie's$16.25M1.67N/AN/AN/A∞CLNNClene$350K111.13N/AN/A$2.09 per share2.07GRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/AINTIInhibitor TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHUCCharlie's-$2.09M-$0.01N/A∞N/A-24.96%N/A-61.40%8/18/2025 (Estimated)CLNNClene-$49.50M-$4.04N/AN/AN/A-8,556.77%-1,106.30%-85.11%8/6/2025 (Estimated)GRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%6/20/2025 (Estimated)INTIInhibitor Therapeutics-$3.03M-$0.01N/A∞N/AN/A-70.65%-40.64%8/4/2025 (Estimated)Latest INTI, GRCE, CLNN, and CHUC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23N/AN/AN/AN/AN/A5/29/2025Q4 2024CHUCCharlie'sN/A-$0.01N/A-$0.01N/A$1.78 million5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 million3/28/2025Q4 2024INTIInhibitor TherapeuticsN/A-$0.01N/A-$0.01N/AN/A3/24/2025Q4 2024CLNNClene-$1.21-$1.67-$0.46-$1.67$0.13 million$0.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHUCCharlie'sN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AINTIInhibitor TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHUCCharlie'sN/A0.740.23CLNNCleneN/A0.830.82GRCEGrace TherapeuticsN/A6.066.06INTIInhibitor TherapeuticsN/A144.77144.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHUCCharlie's7.80%CLNNClene23.28%GRCEGrace Therapeutics6.08%INTIInhibitor TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCHUCCharlie's22.40%CLNNClene35.30%GRCEGrace Therapeutics13.51%INTIInhibitor Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHUCCharlie's40257.35 million199.69 millionNot OptionableCLNNClene1008.98 million6.24 millionOptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/AINTIInhibitor Therapeutics1172.57 million164.34 millionNot OptionableINTI, GRCE, CLNN, and CHUC HeadlinesRecent News About These CompaniesEli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1BMay 27, 2025 | fiercebiotech.comDeep Dive: Checkpoint Inhibitors at a CrossroadsMay 20, 2025 | biospace.comSterol 14 Alpha-Demethylase Inhibitor: 2025 Pipeline Therapeutics Landscape and Growth ProspectsMay 8, 2025 | uk.finance.yahoo.comRAGE Inhibitor Pipeline Insight Report 2025 Analyzes RAGE Inhibitor Drugs, Key Players, and Development ActivitiesApril 30, 2025 | finance.yahoo.comFirst-in-class, oral small-molecule SERCA inhibitor for synucleinopathiesApril 23, 2025 | bioworld.comDianthus Therapeutics: Complement Therapy Developer With Long Road AheadApril 23, 2025 | seekingalpha.comTonner Drones Obtains Patent For Inhibitor In The United StatesApril 23, 2025 | finance.yahoo.comMomentum Therapeutics discovers new RIPK3 inhibitorsApril 17, 2025 | bioworld.comNRG Therapeutics discovers new MPT inhibitorsApril 5, 2025 | bioworld.comVISTA Inhibitor Clinical Trials Market Size FDA Approval Patent Report 2025April 2, 2025 | manilatimes.netPeptide screening reveals irreversible inhibitors for cancer's 'undruggable' cJun proteinMarch 21, 2025 | msn.comIndaptus Therapeutics initiates Phase 1 study of Decoy20March 19, 2025 | markets.businessinsider.comRakovina advances ATR inhibitors into preclinical testingMarch 14, 2025 | bioworld.comNext-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical TestingMarch 12, 2025 | markets.businessinsider.comJanus Kinase (JAK) Inhibitor Pipeline Market Insights Report 2025: Comprehensive Review of 50+ Companies and Respective 55+ DrugsMarch 4, 2025 | finance.yahoo.comHDAC Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsightFebruary 11, 2025 | theglobeandmail.comAceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025February 8, 2025 | businesswire.comScorpion stinger bringer of more PI3Kα inhibitor deals?February 7, 2025 | bioworld.comEli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5BJanuary 14, 2025 | precisionmedicineonline.comOdyssey Therapeutics patent describes RIPK2 inhibitorsJanuary 14, 2025 | bioworld.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsWhat Ray Dalio's Latest Moves Tell Investors By Gabriel Osorio-Mazilli | May 19, 2025View What Ray Dalio's Latest Moves Tell Investors What the New Quarter Says About Super Micro Computer's FutureBy Gabriel Osorio-Mazilli | May 7, 2025View What the New Quarter Says About Super Micro Computer's FutureWhy Dollar General May Be Retail’s Most Undervalued ReboundBy Jeffrey Neal Johnson | June 2, 2025View Why Dollar General May Be Retail’s Most Undervalued ReboundINTI, GRCE, CLNN, and CHUC Company DescriptionsCharlie's OTCMKTS:CHUC$0.11 0.00 (-1.40%) As of 06/5/2025 03:48 PM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.Clene NASDAQ:CLNN$4.33 +0.31 (+7.71%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$4.32 0.00 (-0.12%) As of 06/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Grace Therapeutics NASDAQ:GRCE$2.96 +0.08 (+2.78%) As of 06/5/2025 03:59 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Inhibitor Therapeutics OTCMKTS:INTI$0.05 +0.00 (+8.00%) As of 06/5/2025 03:54 PM EasternInhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
